15/08
AmoyDx Collaborates with AstraZeneca to Develop a HER2 Companion Diagnostic for Lung Cancer in China
We are thrilled to announce that AmoyDx reaches a new collaboration agreement with AstraZeneca. Under this agreement, the AmoyDx® Essential NGS panel will be used as a companion diagnostic of ENHERTU® to identify HER2 (ERBB2) mutations in patients with no
24/07
AmoyDx Signed a Collaboration Agreement with AstraZeneca for HRD Companion Diagnostic
Amoy Diagnostics Co., Ltd (AmoyDx), a China-based innovative molecular diagnostics company (SZSE: 300685), announced that it has entered into a Companion Diagnostic Collaboration Agreement with AstraZeneca (LSE/STO/Nasdaq: AZN), a global biopharmaceutical
08/05
Meet our team at 2023 ASCO Annual Meeting in Chicago, June 2-6
Amoydx will be attending the 2023 ASCO Annual meeting held in Chicago, IL from June 2-6.
26/04
Visit us at PrecisionMed Exhibition and Summit 2023
We will be attending the PrecisionMed Exhibition and Summit 2023 at Dubai World Trade Center from May 23-24. 
27/03
AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as a Companion Diagnostic for selpercatinib RET fusion positive NSCLC
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx PLC Panel”) as a companion diagnostic for RET fusion-positive non-small cell lung cancer (“NSCLC”), for selpercatinib capsules 40 mg
24/03
AmoyDx will be attending the 2023 AACR Annual Meeting in Florida
Say hello to us at booth 1220 and learn more about our companion diagnostic solutions.
Inquiry
* Required information
Manage your account info
Change your password